<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521297</url>
  </required_header>
  <id_info>
    <org_study_id>PBC-UDCA</org_study_id>
    <nct_id>NCT03521297</nct_id>
  </id_info>
  <brief_title>Curative Effect Observation of UDCA Combined Probiotics Therapy in PBC of Poor Response to UDCA</brief_title>
  <acronym>CEOBOFUCPTIP</acronym>
  <official_title>The Comparison of Curative Effects of UDCA Combined Probiotics With Single UDCA Therapy in Primary Biliary Cholangitis of Poor Response to UDCA: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Comparison of curative effects of UDCA combined probiotics with single UDCA therapy in
      primary biliary cholangitis of poor response to UDCA: A Randomized Controlled Trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PBC patients selected for this study, according to Paris-â…¡standard is divided into an UDCA
      full answer group and the other UDCA Poor response groups, two groups of feces were collected
      to study the differences in fecal flora. The patients who are poor responding to UDCA are
      then randomly divided into the two groups, and one continues single UDCA treat, and the other
      group was treated with the UDCA combined probiotics. We will observe the differences of the
      fecal flora, biochemical, immunological and hepatic fibrosis index after 6 months, and
      estimating the long-term prognosis of PBC patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized parallel control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>single(Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical response</measure>
    <time_frame>6 month</time_frame>
    <description>The change of bilirubin and alkaline phosphatase after 6 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Basic indicators</measure>
    <time_frame>6 month</time_frame>
    <description>The change of AST , ALB , PLT , PT and Flex Imaging indexes after 6 month treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>single UDCA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>0.25g UDCA po third per day for 6 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UDCA combined probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25g UDCA po third per day and 2g Live Combined Bifidobacterium and Lactobacillus Tablets po third per day for 6 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UDCA combined probiotics</intervention_name>
    <description>0.25g UDCA po third per day and 2g Live Combined Bifidobacterium and Lactobacillus Tablets po third per day for 6 month</description>
    <arm_group_label>UDCA combined probiotics</arm_group_label>
    <other_name>treatment group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PBC patients (consistent with 2009 Year AASLD Diagnostic criteria), and orally UDCA
             treatment more than 6 month;

          2. Age 30-70 years old;

          3. currently only UDCA treatment, no glucocorticoids and immunosuppressor treatment.

        Exclusion Criteria:

        viral liver disease, alcoholic liver disease, fatty liver, drug-induced liver damage,
        infectious diseases, obesity, diabetes, gastrointestinal diseases, combined with other
        autoimmune diseases, cardiac and pulmonary dysfunction, renal dysfunction, malignancy,
        neurological and psychiatric abnormalities, near 2 months to take antibiotics and
        probiotics, nearly 3 months to participate in other drug clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin B Liang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Third Affliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin B Liang, MD</last_name>
    <phone>13924129928</phone>
    <email>lamikin@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin B Liang, MD</last_name>
      <phone>86-20-85253165</phone>
      <email>lamikin@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 28, 2018</last_update_submitted>
  <last_update_submitted_qc>April 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lin Bingliang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

